Edition:
India

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

59.00USD
12:51am IST
Change (% chg)

$0.30 (+0.51%)
Prev Close
$58.70
Open
$58.65
Day's High
$59.00
Day's Low
$57.50
Volume
57,889
Avg. Vol
175,510
52-wk High
$66.25
52-wk Low
$35.25

Select another date:

Fri, Nov 17 2017

BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial

* Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan

BRIEF-Aerie Pharmaceuticals Q3 loss per share $0.89

* Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-Aerie Pharmaceuticals appoints John Maltman as vice president of medical affairs

* Aerie Pharmaceuticals announces appointment of John Maltman, PH.D., as vice president of medical affairs Source text for Eikon: Further company coverage:

BRIEF-Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa

* Aerie Pharmaceuticals announces FDA advisory committee vote in favor of Rhopressa (netarsudil ophthalmic solution) 0.02%

U.S. FDA panel backs Aerie's glaucoma drug Rhopressa

Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

UPDATE 1-U.S. FDA panel backs Aerie's glaucoma drug Rhopressa

Oct 13 Aerie Pharmaceuticals Inc's experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

Aerie's glaucoma drug Rhopressa wins backing from U.S. FDA panel

Oct 13 The benefit of Aerie Pharmaceuticals Inc's experimental glaucoma treatment outweighs the risks and the drug should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Friday.

BRIEF-Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa

* Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​ Source text for Eikon: Further company coverage:

UPDATE 2-FDA review says Aerie glaucoma drug effectively lowers eye pressure; shares jump

Oct 11 Aerie Pharmaceuticals Inc's experimental glaucoma treatment Rhopressa is effective in lowering eye pressure a preliminary review by the U.S. Food and Drug Administration, has concluded, sending Aerie's shares up as much as 19 percent.

Aerie's glaucoma drug effectively lowers eye pressure: FDA review

Aerie Pharmaceuticals Inc's experimental glaucoma treatment Rhopressa is effective in lowering eye pressure, a preliminary review by the U.S. Food and Drug Administration concluded.

Select another date: